Alzheimer Disease Drugs: Cholinesterase Inhibitors, Memantine and Anti-Amyloid Therapy in 2026

Educational pharmacology review updated 10 November 2026. This material does not replace clinical evaluation, local licensing rules or patient-specific prescribing guidance.

Overview

Alzheimer disease (AD) is a progressive neurodegenerative illness associated with amyloid-β pathology, tau changes and loss of neuronal networks. Drug treatment includes symptomatic cognitive therapies and, for carefully selected patients with early symptomatic, amyloid-confirmed disease, anti-amyloid monoclonal antibodies that may slow decline but do not cure AD [1–3].

Symptomatic drug mechanisms

  • Donepezil: a reversible acetylcholinesterase inhibitor, generally prescribed for mild-to-severe AD according to national approval.
  • Rivastigmine: a carbamate cholinesterase inhibitor affecting acetyl- and butyrylcholinesterase; available orally and by patch.
  • Galantamine: a reversible acetylcholinesterase inhibitor with nicotinic receptor modulatory actions.
  • Memantine: a low-to-moderate affinity uncompetitive NMDA receptor antagonist for moderate-to-severe AD, sometimes combined with a cholinesterase inhibitor.

Donepezil is not a carbamate, and these medicines are not shown to reverse established neurodegeneration [1].

Symptomatic treatment adverse effects and interactions

Cholinesterase inhibitors commonly cause nausea, vomiting, diarrhea, anorexia and weight loss. Bradycardia, syncope and conduction disturbances can occur, particularly with other heart-rate-lowering drugs. Rivastigmine patches reduce some GI intolerance but can cause skin reactions; patch handling instructions must be followed precisely. Memantine may cause dizziness, headache or confusion and needs renal-dose review. Assess practical benefit, tolerability and caregiver goals periodically [1].

Disease-modifying anti-amyloid antibodies

Lecanemab and donanemab target aggregated amyloid-β and are authorized in the United States for selected patients with mild cognitive impairment due to AD or mild AD dementia, with amyloid confirmation before treatment. Their effect is slowing decline on measured outcomes, not restoration of lost cognition. Patient selection typically includes MRI assessment, discussion of APOE ε4-associated risk and cerebrovascular findings, and consideration of concomitant antithrombotic medicines. Aducanumab was discontinued commercially and should not be listed as an ordinary currently available US therapy [2,3].

Amyloid-related imaging abnormalities (ARIA) and MRI surveillance

ARIA can involve cerebral edema/effusions (ARIA-E) or microhemorrhage/siderosis (ARIA-H); it may be asymptomatic or cause headache, confusion, seizures or focal deficits and, rarely, death. APOE ε4 homozygotes have higher ARIA risk. The FDA’s 2025 lecanemab update added an MRI before the third infusion, alongside other label-directed surveillance; the July 2026 US lecanemab label includes IV and subcutaneous formulations with product-specific monitoring. Donanemab requires its own MRI schedule. Neither antibody should be initiated without the infrastructure for assessment and management of ARIA [2,3].

Other treatment and clinical context

Address vascular risk, sleep, mood, caregiver safety and nonpharmacologic support. Many presentations of cognitive decline have treatable contributors such as medication anticholinergic effects, depression, thyroid disease or B12 deficiency. Antipsychotics should be used cautiously in severe dementia-associated behavioral emergencies and not as routine cognitive treatment [1].

Key clinical distinctions

Symptomatic agents modestly improve or stabilize symptoms for a period; monoclonal anti-amyloid therapy attempts to modify the disease trajectory and requires more intensive screening and surveillance. Approvals, reimbursement and treatment eligibility are jurisdiction-specific [2,3].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. US Food and Drug Administration. FDA to recommend additional, earlier MRI monitoring for patients with Alzheimer’s disease taking Leqembi (lecanemab). Drug Safety Communication. 2025 Aug 28. Available from: https://www.fda.gov/drugs/drug-safety-communications/fda-recommend-additional-earlier-mri-monitoring-patients-alzheimers-disease-taking-leqembi-lecanemab
  3. DailyMed. LEQEMBI (lecanemab-irmb) injection, IV or subcutaneous: US prescribing information, updated 2026 Jul 21. Available from: https://dailymed-beta.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d1ff786-e577-410a-a273-c4d7d0e4e975
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *